Bin Liu

Dr. Bin Liu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2025 in Advanced Science
Verified
Journal Article
Open access
YJYongnan Jiang
Yongnan Jiang
QZQingling Zhang
Qingling Zhang
YZYuhan Zhang
Yuhan Zhang
XYXinlu Yu
Xinlu Yu
BJBo Jia
Bo Jia
BLBin Liu
Bin Liu
Current intravesical therapies for bladder cancer after resection are limited by poor tissue penetration, off‐target effects, and insufficient efficacy. To address these challenges, this study designs a thermo‐responsive hydrogel (PNH) that encapsulates chitosan (CS)‐coated Fe/Mn bimetallic nanozymes (FMCC) together with cholesterol oxidase (ChOx). FMCC displays multiple enzyme‐mimicking activities, including peroxidase (POD), catalase (CAT), and glutathione oxidase (GSHox). ChOx amplifies this catalytic cascade, enhancing reactive oxygen species (ROS) production and inducing ferroptosis‐mediated tumor cell death. The CS coating improves mucosal adhesion and tissue permeability, thereby facilitating intravesical delivery. Upon near‐infrared (NIR) irradiation, FMCC generates heat that liquefies the hydrogel, enabling spatiotemporally controlled drug release and providing mild photothermal therapy (MPTT). This photothermal effect acts synergistically with ferroptosis induction and immune modulation, concurrently minimizing damage to normal tissues. In parallel, ChOx disrupts cholesterol‐rich membrane rafts and promotes pro‐inflammatory M1 macrophage polarization. Released Mn 2+ ions further potentiate immune activation by stimulating the cGAS–STING pathway, driving IFN‐β and IL‐6 secretion, dendritic cell maturation, and T cell infiltration. Together, this nanozyme–hydrogel system integrates tissue penetration, metabolic disruption, and immune stimulation, representing a promising strategy for localized bladder cancer therapy.